Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29558920 | 1.00 | KDM4C (0.54) | KDM4CPTGER4ALDH1A1HCAR3GRIN2B | |
| SCHEMBL29159941 | 0.98 | KDM4C (0.52) | KDM4CPTGER4ALDH1A1HCAR3GRIN2B | |
| SCHEMBL30020531 | 0.98 | KDM4C (0.52) | KDM4CPTGER4ALDH1A1HCAR3GRIN2B | |
| SCHEMBL30548170 | 0.94 | FGFR1 (0.47) | KDM4CPTGER4GRIN2BHSD17B10GAA | |
| SCHEMBL20268541 | 0.94 | FGFR1 (0.47) | KDM4CPTGER4GRIN2BHSD17B10GAA | |
| SCHEMBL23361781 | 0.94 | FGFR1 (0.47) | KDM4CPTGER4GRIN2BHSD17B10GAA | |
| SCHEMBL29393184 | 0.94 | FGFR1 (0.47) | KDM4CPTGER4GRIN2BHSD17B10GAA | |
| Ammonia Solution, Strong SCHEMBL30676125 | 0.93 | FGFR1 (0.46) | KDM4CPTGER4GRIN2BHSD17B10GAA | |
| Tromethamine SCHEMBL30922345 | 0.87 | KDM4C (0.41) | KDM4CPTGER4CTSDHSD17B10GAA | |
| SCHEMBL29558894 | 0.87 | ALDH1A1 (0.53) | ALDH1A1TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236627-A1 | CERTAIN OCTAHYDROFURO[3,4- B]PYRAZINES AS GLP-1 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2025-07-24 | — | — | US | disclosed |
| EP-4582421-A2 | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING SAME | LG Chem, Ltd. (KR) | 2025-07-09 | — | — | EP | disclosed |
| CN-119923395-A | N-heterocyclic GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods of use thereof | 卡莫特医疗有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20240300928-A1 | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING SAME | LG CHEM, LTD. (KR) | 2024-09-12 | — | — | US | disclosed |
| EP-4373821-A1 | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF | Hepagene Therapeutics (HK) Limited (HK) | 2024-05-29 | — | — | EP | disclosed |
| EP-4303215-A1 | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING SAME | Lg Chem, Ltd. (KR) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023001237-A1 | GLUCAGON-LIKE PEPTIDE-1 RECEPTOR MODULATORS AND USES THEREOF | Hepagene Therapeutics (HK) Limited (CN) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022216094-A1 | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING SAME | 주식회사 엘지화학 | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300928-A1 | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING SAME | GLP1R, GPR119, DMPK | KDM4C 2145/4885PTGER4 2044/4885ALDH1A1 3793/4885 |
| US-20250236627-A1 | CERTAIN OCTAHYDROFURO[3,4- B]PYRAZINES AS GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GPR119 | KDM4C 3266/4885PTGER4 348/4885ALDH1A1 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.